http://www.dailytimes.com.pk/default.asp?page=story_28-6-2004_pg6_16Washington: For the last 20 years, the American pharmaceutical industry has become more of a marketing machine than a discoverer of new and useful drugs.
The industry now sells drugs of dubious benefit using its wealth and power to co-opt every institution that might stand in its way, including Congress, the Food and Drug Administration, academic medical centres and the medical profession itself, according to an expose in the current issue of New York Review of Books.
Americans spent $200 billion on prescription drugs in 2002 through direct purchases at pharmacies and mail order. The figure includes the 25 percent markup for wholesalers, pharmacists and other middlemen and retailers, but not the large amounts spent for drugs administered at hospitals, nursing homes or doctors’ offices. Total worldwide sales for prescription drugs in 2002 were $400 billion, 50 percent of them in the United States. Beginning in 1980, Congress enacted a series of laws designed to speed the translation of tax-supported basic research into useful new products to improve the position of American-owned high- tech businesses in world markets. Businesses and universities were also allowed to patent discoveries emanating from research sponsored by the National Institutes of Health, the major distributor of taxpayer dollars for medical research. Until then, such discoveries were in the public domain, available to any company that wanted to use them. This gave a big boost to the nascent biotechnology industry. Small biotech companies proliferated. They worked in association with universities for drug development, hoping for lucrative deals with big drug companies which could market the new drugs. This freed the dug companies from relying on their own research for new drugs.
<snip>
In 2002, the profits of Big Pharma fell from 18.5 percent to 17 percent of the combined profits of Fortune 500 companies. However, the combined profits of the 10 drug companies were more than the profits of the other 490 businesses put together. The next year, the profits of the Fortune 500 drug companies dropped to 14.3 percent of sales, but still well above the median for all industries of 4.6 percent for that year. The top 10 pharmaceutical companies spent only 11 percent of what they earned in sales on research and development in 1990, the figure rising to 14 percent in 2000. The biggest item in their budget is “marketing and administration, which accounted for 36 percent of their sales revenues in 1990. The proportion remained unchanged over the next decade.
...more...